key: cord-0911815-0xl0k7ra
authors: Kurup, Drishya; Wirblich, Christoph; Diba, Leila Zabihi; Lambert, Rachael; Watson, Megan; Shaikh, Noor; Ramage, Holly; Solomides, Charalambos; Schnell, Matthias J.
title: A single-dose of the deactivated rabies virus vectored COVID-19 vaccine, CORAVAX, is highly efficacious and alleviates lung inflammation in the hamster model
date: 2022-02-23
journal: bioRxiv
DOI: 10.1101/2022.02.21.481324
sha: ba696e95ae87679cff22847b5ee69e04ba5a7d9a
doc_id: 911815
cord_uid: 0xl0k7ra

Without sufficient herd immunity through either vaccination or natural infection, the Coronavirus Disease 2019 pandemic is unlikely to be controlled. Waning immunity with the currently approved vaccines suggests the need to evaluate vaccines causing the induction of long-term responses. Here we report the immunogenicity and efficacy of our adjuvanted single-dose Rabies vectored SARS CoV-2 S1 vaccine, CORAVAX, in hamsters. CORAVAX induces high SARS CoV-2 S1 specific and virus-neutralizing antibodies (VNA) that prevent weight loss, viral loads, disease, lung inflammation, and the cytokine storm in hamsters. We also observed high Rabies VNA titers. In summary, CORAVAX is a promising dual antigen vaccine candidate for clinical evaluation against SARS CoV-2 and Rabies virus.

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) originated in Wuhan, China, 24 in December 2019 and accounts for over 264 million infections and 5.22 million deaths at the time 25 of this report 1 . SARS Cov-2 infection in humans causes coronavirus-19 disease , 26 resulting in mild or severe clinical manifestations that mainly affect the respiratory system. CoV-2 S protein based vaccines that induce neutralizing antibodies 2 . Recent studies suggest that 33 neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-34

CoV-2 infection 3 . Whereas the previous SARS CoV was controlled using social isolation and 35 screening, control of the spread of SARS CoV-2 has proven very challenging. Several countries 36 began administering vaccines by December 2020 and into early January 2021. Despite these 37 efforts, controlling the pandemic has been difficult due to several factors: 1) high transmissibility, 38 column equilibrated in PBS. After washing with ten-bed volumes of PBS, the column was loaded 150 with two column volumes of HA peptide at a 400 μg/ml concentration in PBS and incubated 151 overnight at 4˚C. The following day, the protein was eluted with two column volumes of HA 152 peptide followed by two column volumes of PBS. Fractions were collected and analyzed by 153 western blotting with polyclonal antiserum against the S1 domain (Thermo Fisher, Cat# 154 PA581798). Peak fractions were then pooled and dialyzed against PBS in 10,000 molecular weight 155 cutoff (MWCO) dialysis cassettes (Thermo Fisher Scientific) to remove excess HA peptides. After 156 dialysis, the protein was quantitated by UV spectrophotometry and frozen in small aliquots at −80 157 ˚C. were then pooled and dialyzed against PBS in 10,000 molecular weight cutoff (MWCO) dialysis 175 cassettes (Thermo Fisher Scientific). After dialysis, the protein was quantitated by UV 176 spectrophotometry and frozen in small aliquots at −80 ˚C. 177 178

To determine antibody responses to the S protein of SARS-CoV-2, an indirect ELISA was 180 developed utilizing purified S1 or receptor-binding domain (RBD) protein. The production of the 181 recombinant proteins is described above. An indirect ELISA measured humoral responses to 182 SARS-CoV-2 S1 and RBD protein. We tested individual hamster sera by enzyme-linked 183 immunosorbent assay (ELISA) for the presence of IgG specific to SARS-CoV-2 S1 or RBD. To 184 test for anti-SARS CoV-2 S1 humoral responses, we produced soluble S1 or RBD as described 185

above. The two recombinant proteins were resuspended in coating buffer (50 mM Na2CO3 [pH 186 9.6]) at a concentration of 0.5 μg/mL of S1 or 1 μg/mL of RBD, and then they were plated in 96-187 well ELISA MaxiSorp plates (Nunc) at 100 μl in each well. After overnight incubation at 4°C, 188 plates were washed three times with 1× PBST (0.05% Tween 20 in 1× PBS), followed by the 189 addition of 250 μl blocking buffer (5% dry milk powder in 1× PBST) and incubation at room 190 

Sera collected from animals were tested for neutralizing capabilities against SARS-CoV-2. Briefly, 208 serum samples were heat-inactivated (30 min at 56°C) and then diluted at 1:10. The diluted sera 209 were serially diluted two-fold in a 96 well plate, and 30 μl of each serum dilution was mixed with 210 30 μl of SARS-CoV-2-WA (100 PFU). The serum/virus mixtures were incubated for 1 h at room 211 temperature; 60 μl of the serum/virus mixtures were then transferred to Vero E6 cell monolayers 212 in flat-bottom 96-well plates and incubated for two days at 37°C. Plates were fixed with 4 % PFA 213 and removed from containment. Plates were blocked and then stained with DAPI at 0.5 g/mL, 214 and a SARS-CoV-2 specific human antibody CR3022 (produced in-house from plasmids-BEI, 215 NR-53260) conjugated with a Dylight 650 fluorophore at a concentration of 4 g/mL in 1X DPBS 216 with 5% FBS. Plates were imaged and read on a Cytation5 plate reader (Biotek). 217

Rapid fluorescent focus inhibition tests (RFFIT) were performed as previously described 12 

Animals were euthanized on days 3, 7, or 14 post-challenge (p.c.), and lungs and nasal turbinates 238 were harvested. One lobe of the right lung, right kidney, and right nasal turbinates was placed in 239 pre-filled tubes containing 1 mL viral transport medium for viral load analysis. The right lung (one 240 lobe), left nasal turbinates, left kidney, and spleen was placed in pre-filled tubes containing 1mL TRIzol reagent. The left lung lobe was perfused with 4% Formaldehyde, placed in a conical tube 242 filled with 6 mL of 4% Formaldehyde, and put on ice. The lung samples were placed in 4C for 243 three days before processing for histology and staining. 244 245

Tubes containing organs in viral transport medium were homogenized using the BeadBlaster 24R 247 homogenizer, and tissue homogenates were aliquoted and stored at -80˚C. Tissue homogenates 248

were titrated by TCID50 assay on Vero E6 cell monolayers (ATCC) in 96-well plates to determine 249 viral loads. Plates were incubated for 2 days at 37˚C before being fixed with 4 % PFA and removed 250 from containment. Plates were blocked and then stained with DAPI at 0.5 g/mL, and a SARS-251

CoV-2 specific human antibody CR3022 (produced in-house from plasmids-BEI, NR-53260) 252 conjugated with a Dylight 650 fluorophore at a concentration of 4 g/mL in 1X DPBS with 5% 253 FBS. Plates were imaged and read on a Cytation5 plate reader (Biotek). The limit of detection was 254 determined by mixing 1000 PFU/mL, 100 PFU/mL, 50 PFU/mL, and 10 PFU/mL of a known titer 255 SARS CoV-2 WA strain virus with lung or tissue homogenates followed by TCID50 assay to 256 calculate the limit of detection. 257 

The assay was performed in 96-well, flat, white-bottom plates (Corning) preseeded with 30,000 301

full-length SARS CoV-2 spike at an MOI of 0.5. After 60 h, the medium was removed, and 25 μl 303 of assay buffer (RPMI 1640 with 4% low-IgG FBS) was added to each well. Sera were pooled 304 from each group and heat-inactivated for analysis. Then, 25 μl sera at a starting dilution of 1:30 305 were serially diluted 3-fold in assay buffer (in duplicates). The sera were then incubated with the 306 infected cells for 30 min at 37°C. Post-challenge (day 15 post-challenge) hamster sera from the 307 unvaccinated challenged group are used as a control. Genetically modified Jurkat cells expressing 308 mouse FcγR IV with a luciferase reporter gene under the transcriptional control of nuclear-factor-activated T cell (NFAT) promoter were added at 1.5 × 10 5 cells in 25 μl per well, which is 310 approximately a 5:1 ratio of effector cells (Promega) to target cells. Cells were then incubated for 311 another 6 h at 37°C. After the incubation, 75μL Bio-Glo Luciferase assay reagent was added, and 312 luminescence was quantified using a microplate reader. Fold induction was measured in relative 313 

An unpaired two-tailed nonparametric t-test (Mann Whitney) was performed on log-transformed 321 data for each time point for the ELISA, virus-neutralizing antibody, viral load, and qPCR assays. 322

An unpaired nonparametric two-tailed Mann Whitney test was performed on percentage weights 323 for each time point for the weight curves. P values are reported.

We previously described the Rabies virus vectored SARS COV-2 vaccine CORAVAX™ 11 . 327

Utilizing the SAD-B19 Rabies vaccine strain, the S1 subunit of the SARS-CoV-2 spike protein 328 (S) was incorporated into RABV virions. To promote the incorporation of the S1 domain, we 329 constructed a gene encoding a fusion protein between 682aa of the N-terminal of SARS-CoV-2 S 330 fused to a C-terminal domain of RABV glycoprotein (G) 11 . Two doses of inactivated CORAVAX 331 were efficacious in hamsters and mice and induced high virus-neutralizing antibodies (VNA) 11, 13 . 332

Here, we evaluated the effectiveness of a single-dose of CORAVAX in the Syrian hamster model. To analyze the immunogenicity of the CORAVAX vaccine, the sera from both groups of hamsters 342

were assayed for SARS CoV-2 specific antibody responses by ELISA specific for SARS-CoV-2 343 S1 as well as the receptor-binding site (RBD) (Fig 2) . We observed high SARS CoV-2 S1 and 344 RBD-specific IgG responses in the CORAVAX group as early as day 14 post-vaccination. These 345 responses were significantly increased until day 28 (Fig 2A, B) , indicating the long-term in-vivo 346 stability of the antigen. As previously reported for CORAVAX with another adjuvant, we observed a strong Th1 biased immune response on day 28 indicated by the induction of S1 IgG2/3 responses 348 ( Fig 2C) . As expected, no SARS-CoV-2 S1 or RBD-specific immune response was detected before 349 the challenge in the control animals vaccinated with the EBOV vaccine FILORAB1 (Fig 2A, B , 350 C). These results suggested that a single inoculation may provide some level of protection. 351

We analyzed the sera post-challenge (p.c.). Of note, on day 3 p.c. (day 42), we observed S1 IgG 353 and IgG2/3, and RBD IgG responses only in the CORAVAX vaccinated animals, except one 354 animal in the control group, which had a low level of RBD IgG responses (Fig 2A, B , C). On days 355 7 and 14 p.c. (day 46 and 52), we observed significantly increased S1 IgG responses in the 356 CORAVAX group, which were significantly higher than the responses seen in the control group 357 (Fig 2A) . Moreover, the CORAVAX vaccinated animals induced a strong Th1 biased immune 358 response on time points post-challenge, a feature previously shown to be beneficial in combatting 359 SARS-CoV-2 infection 15 . In contrast, control animals immunized with FILORAB1 induced either 360 no S1 IgG2/3 responses or low levels in the case of two animals only on day 14 p.c. (day 53) (Fig  361   2C ). As previously reported, we detected no significant differences in immune responses against 362 the RBD IgG responses on days 7 and 14 p.c. for all groups (Fig 2B) . 363

While the ELISA data is helpful to follow immune responses over time and analyze the quality of 365 such responses, we tested the potency of the sera to neutralize SARS CoV-2 using a virus 366 neutralization antibody (VNA) assay. As shown in figure 3, VNA titers against SARS-CoV-2 in 367 the CORAVAX group followed the trend seen in the S1 IgG ELISA, wherein high VNA titers 368 were detected on day 28, maintained on day 3 p.c., and increased on days 7 and 14 p.c. We did not 369 detect 100% VNA titers on day 14 p.c., which may reflect levels lower than our limit of detection (dilution 1:20) (Fig 3) . However, VNA was present for CORAVAX immunized animals before 371 the challenge (day 28), and no VNA titers were observed in the FILORAB1 group. The 372 FILORAB1 group had no detectable VNA titers at day 3 p.c (similar to S1 IgG responses), but 373 some VNAs were detected on days 3 and 7 after the challenge. Of note, VNA titers of the 374 FILORAB1 group are significantly lower than the CORAVAX group. On day 14 p.c. CORAVAX 375 immunized animals showed VNA response surpassing responses detected for human convalescent 376 sera. No background neutralization was observed in the negative control human sera (Fig 3) . 377

In addition to the VNA detected for SARS-CoV-2, we also analyzed the VNA induced by the two 380 vaccines against RABV and observed no significant differences between the CORAVAX and the 381 FILORAB1 group (Fig S1) . The CORAVAX and the FILORAB1 vaccine induced strong RABV 382 VNA titers exceeding the protective levels against RABV, i.e., 0.5 IU/mL. 383

As shown above, CORAVAX is immunogenic; therefore, the hamsters were challenged 387 intranasally on day 39 with 10 4 PFU of SARS-CoV-2 isolate USA_WA1/2020 and were monitored 388 for up to 14 days. The CORAVAX vaccinated animals showed significantly less weight loss than 389 the FILORAB1 controls, which lost more than 6% weight (Fig 4) . On days 3, 7, and 14 p.c., five 390 hamsters in each study group were humanely euthanized, and lungs, nasal turbinates, spleen, and 391 kidneys were harvested. The viral loads were determined by assaying RNA for viral copies of 392

replicating virus for the subgenomic (sg) mRNA by RT-qPCR assay (Fig 5A, B) and infectious viral loads by TCID50 assay (Fig 5C, D) . Significantly lower sgmRNA and infectious viral loads 394 were detected in the lungs of the CORAVAX vaccinated animals on day 3 post-challenge (Fig 5A,  395 C). On day 7 post-challenge, significantly lower sgmRNA was detected in the lungs of the 396 CORAVAX group, but no detectable infectious virus was seen in either the vaccine or control 397 groups (Fig 5A, C) , suggesting RNA stability. On day 14 post-challenge, there was no detectable 398 infectious SARS-CoV-2 in either group, although similarly low levels of sgmRNA were detected 399 in both groups (Fig 5A, C) . In the nasal turbinates, we only detected infectious virus on day 3 p.c. 400 with no significant differences between the two groups. (Fig 5B,D) . We could not detect infectious 401 virus or sgmRNA in the kidneys or spleens of animals in either group (data not shown). 402

Lung sections were collected from control and vaccinated animals at days 3,7, and 14 p.c. and 405 processed for histology (Figs 6,7,8 ). Sections were scored in a blinded manner (Scoring criteria, 406 Table S1 ). On day 3 p.c., the control, FILORAB1 specimens showed severe, patchy inflammation 407 involving more than 50% of the examined lung with severe involvement of the airways 408 (bronchitis/bronchiolitis), extending into the alveolar septa (pneumonitis) with alveolar edema and 409 hemorrhage. We also noted severe vasculitis. The immunohistochemical stain for the SARS-CoV-410 2 Nucleoprotein antigen showed extensive multifocal positive cells involving bronchial 411 epithelium, alveolar epithelium, and macrophages. In contrast, on day 3 p.c., the CORAVAX 412 vaccinated specimens showed only mild to moderate patchy inflammation involving less than 50% 413 of the examined lung with mild to moderate airway inflammation, mild alveolar wall infiltration, 414 congestion, and interstitial edema. We also noted focal mild vasculitis. Immunohistochemical stain 415

for the SARS-CoV-2 Nucleoprotein antigen showed only multifocal positive bronchial cells. 416 On day 7 p.c., the control FILORAB1 specimens still showed significant inflammation involving 418 around 50% of the examined lung. The disease is multifocal, nodular, and bronchiolocentric with 419 moderate to severe involvement of the airways and alveolar wall infiltration, edema, congestion, 420 and focal hemorrhage. We also noted mild to moderate vasculitis. Immunohistochemical stain for 421 the SARS-CoV-2 Nucleoprotein antigen showed multifocal positive cells involving both bronchial 422 epithelia and alveolar epithelia but to a much lesser extent than those observed on day 3 p.c. On 423 day 7, the CORAVAX vaccinated group showed significant improvement with only mild airway 424 inflammation, mild alveolar edema, and congestion involving less than 30% of the examined lung. 425

Nucleoprotein antigen showed no definite positive cells. 427

On day 14 p.c., the control FILORAB1 specimens showed improvement, with inflammation 428 involving less than 30% of the lung with mild to moderate airway inflammation, mild to moderate 429 alveolar congestion, edema, and mild vasculitis. Immunohistochemical stain for the SARS-CoV- Table S2 ), normalized to -441 actin and expressed as fold-changes over the average expression of three uninfected, unchallenged 442 hamsters. On days 3 and/or 7 post-challenge, we observed significantly higher levels of 443 inflammatory cytokines IFN-, IFN-, IL-10, and IL-6 in the control groups than were detected in 444 CORAVAX immunized animals (Fig 9) . CCL5 and IL-4 were only detectable in the control 445 groups, suggesting a more substantial Th2 bias in the control group, as seen in the isotype-specific 446 ELISA presented above (Fig 2C) . On day 7 p.c., there was a significant upregulation of CCL3, IL-447 2, IL-21, and TGF-b1 in the CORAVAX vaccinated animals, which may have contributed to 448 dampening the inflammation and allowing for viral clearance as observed in the lung histology 449 (Fig 6B, C, and 7B, C) . We saw no significant difference in the IL-17 and IL-12 p40 expression 450 between the two groups after the challenge (Fig 9 and S2) . 451

While we previously found high VNA titers in animals immunized with CORAVAX, we wanted 455 to test if CORAVAX also induced non-neutralizing antibody functions. To understand the 456 potential mechanism of S1 antibody-mediated protection, we tested pre-challenge hamster sera 457 The emergence of variants in the presence of waning vaccine immunity has raised concerns 502 worldwide. A major current issue is that all vaccines express the ancestral SARS-CoV-2 spike, 503

whereas the currently circulating variants, including Delta and Omicron, have significant 504 mutations in the spike-encoding region, rendering the vaccine less effective giving rise to mutants. 505

Generating and testing new variant vaccines may be required to control the spread of SARS CoV-506 2. Single-dose variant vaccines that can induce long-term immunity may help to improve vaccine 507 coverage and reduce reinfection rates. Testing vaccines in previously infected animals may 508 become critical as infection rates rise worldwide. In addition, developing standardized assays to 509 determine the virus-neutralizing titer (VNT) thresholds essential for protection may improve 510 vaccine quality 34 . 511

Here we report the immunogenicity, efficacy, reduced lung inflammation, and a potential 513 mechanism of our single-dose S1-based COVID-19 vaccine, CORAVAX, in hamsters. The 514 antigen used is a chimeric protein that contains the S1 domain (1-682aa) fused to the C terminus 515 of RABV-G for tethering to the Rabies virus virion. We previously analyzed the correct folding 516 of our chimeric S1 in CORAVAX by verifying its binding to hACE2 protein 11 . An S1 based 517 vaccine, when folded correctly, might serve as a good immunogen as it ensures the immune 518 responses against the important neutralizing epitopes identified in human convalescent patients 519 that recognize the RBD, NTD S1, and quaternary epitope that bridges the two RBDs 35 . 520

Our previous study showed that two doses of CORAVAX adjuvanted with MPLA-Addavax, a 522 TRL4 agonist, induced high levels of neutralizing antibodies, generated a strong Th1-biased 523 immune response (indicated by high S1 IgG2/3 responses), and were efficacious in hamsters with 524 viral clearance in the nasal turbinates 13 . In human patients with mild/recovered COVID-19, a Th1 525 biased immune response is beneficial for protection against disease 36 . The current study used 526 SEPIVAC SWE (developed by VFI and Seppic) adjuvant, a squalene-in-water emulsion, similar 527

to Addavax (Invivogen) tested in our previous study. We observed a significant increase in 528 antibody and VNT's from day 14 to day 28 with a single-dose of adjuvanted inactivated 529 CORAVAX, suggesting antigen stability. Of note, CORAVAX induced high 100% VNT titers. 530

As previously published, CORAVAX induced a strong Th1 biased immune response, which 531 helped significantly reduce inflammation and viral loads in the lungs. The controls induced a 532 stronger inflammatory cytokine and chemokine response in the lungs on day 3 and/ day 7 post-533 challenge than the vaccinated animals, in addition to the Th2 cytokines only being induced in the 534 control group. Sera from CORAVAX vaccinated hamsters demonstrate antibody-dependent 535 cytotoxic activity, suggesting a dual function of the antibodies. Therefore, we can conclude that a 536 single-dose of CORAVAX is efficacious and prevents weight loss and the cytokine storm seen in 537 the control lungs. 538

The histopathologic tissue examination on days 3 and 7 p.c. showed the CORAVAX vaccinated 540 animals had significantly reduced inflammation, as indicated by the accumulation of inflammatory 541 cells compared to the controls. CORAVAX vaccinated animals always had significantly lower 542 average pathology lung scores, indicating excellent protection from lung disease. A significantly 543 higher amount of antigen was detected in the lungs of the controls than in the CORAVAX 544 vaccinated animals on days 3 and 7 p.c. By day 14 p.c., the inflammation was completely cleared 545 in the vaccinated animals and significantly reduced in the control unvaccinated group, and the 546 antigen was absent in the lungs of both groups, which is a common feature of the hamster model. 547

The hamster model is well established for SARS CoV-2 as it mimics the human lung pathology 548 seen in COVID-19 patients 16 . This study concludes that SARS CoV-2 challenged CORAVAX 549 vaccinated animals never developed the severe inflammation associated with the disease 550 (compared with the control animals). We also observed a rapid decline and early elimination of Hamsters were challenged intranasally with 10 4 PFU SARS-CoV-2, and five of the animals in 607 each group were euthanized on days 3, 7, and 14 p.c. Right lungs (A, C) and nasal turbinates (B, 608 D) from each animal were homogenized in media, and viral loads were determined by qRT-PCR 609 (A, B) or by plaque assays on Vero E6 cells (C, D). The limit of detection for the qRT-PCR assay 610 is 10 copies. The limit of detection for the plaque assay was 50 PFU/mL per lung/nasal turbinate 611 tissue. The CORAVAX vaccine group is shown in blue, and the FILORAB1 group in black. Data 612 represent mean ± S.D., N = 5 for FILORAB1 group days 3, 7, and 14 time points, and N = 5 for 613 CORAVAX group days 3, 7, and 15 time points. P values determined by Mann-Whitney test. Only 614 significant differences are depicted. 615 Overall lung pathology scores at days 3-, 7-and 14-days p.c. The pathology scores (mean) were 626 calculated based on the criteria described in Table S1 . The CORAVAX vaccine group is shown in 627 blue, and the control group in black. Data represent mean ± S.D., N = 5 for FILORAB1 group and 628 CORAVAX group for days 3,7 and 15 time points. P > 0.123 (ns), P < 0.033 (*), P < 0.002 (**), 629 P < 0.001 (***). Only significant differences are depicted. Table S1 . Semi-quantitative histopathological scoring criteria.

a Total score = the scores of general assessment × the scores accumulated from individual category assessment b More than one lung lobes should be examined for histological assessment, if only one lobe were studied, percentage of the total lung cutting area would be used for scoring. Adapted from Lee et al. 2020 1 . 

Assessment percentage of lung damage area under 4x objective lens 0 none 1 focal lung inflammation within one lobe or <30% of total lung cutting area b 2 diffuse lung inflammation within one lobe or involving 30-70% total lung cutting area 3 diffuse lung inflammation involving more than one lobe or 70% total lung cutting area Bronchioles (B) Assessing appearance and severity of peribronchiolar infiltration, intrabronchiolar wall infiltration and bronchiolar epithelial cell death/desquamation 0 none 1 peribronchiolar infiltration only 2 peribronchiolar and epithelial infiltration (mild to moderate) 3 severe bronchiolar wall infiltration and epithelium desquamation Alveoli (A) Assessing the appearance, scope involved, and severity of alveolar septal infiltration, alveolar space infiltration, alveolar space exudation and hemorrhage 0 none 1 only alveolar wall thickening (interstitial congestion and edema), mild interstitial pneumonitis (<30%) 2 alveolar wall infiltration (interstitial pneumonitis), exudation or hemorrhage involving 30-70% of lung cutting area 3 diffuse alveolar infiltration (interstitial pneumonitis), exudation or hemorrhage involving >70% of lung cutting area Vasculature (V) Severity of vasculature inflammation 0 none, 1 only perivascular edema and or perivascular infiltration 2 mild infiltration within the vessel wall without endothelium infiltration 3 severe vasculitis

Coronavirus Pandemic (COVID-19)". Our World in Data

SARS-CoV-2 vaccines -the biggest medical research project of 679 the 21st century

Neutralizing antibody levels are highly predictive of immune 681 protection from symptomatic SARS-CoV-2 infection

Comparative Effectiveness and Antibody Responses to Moderna and 684

COVID-19 Vaccines among Hospitalized Veterans -Five Veterans Affairs 685

Comparative Effectiveness of Moderna

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

A single intranasal dose of a live-attenuated parainfluenza virus-vectored 696 SARS-CoV-2 vaccine is protective in hamsters

Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. 703 EBioMedicine 68

Rabies virus-based COVID-19 vaccine 705 CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2

Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces 708 Long-term Immunity in Nonhuman Primates

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in 711 a Syrian hamster model

Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization 714

Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge

T helper type (Th1/Th2) responses to SARS-CoV-2 and 717 influenza A (H1N1) virus: From cytokines produced to immune responses

Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, 720 and Non-human Primates

Protective immunity after recovery from SARS-CoV-2 723 infection

The durability of immunity against reinfection by SARS-CoV-2: a 725 comparative evolutionary study

Protection and waning of natural and hybrid COVID-19 immunity. 728 medRxiv

Waning immunity to SARS-CoV-2: implications for vaccine 730 booster strategies

Vaccination after prior COVID-19 infection: Implications for dose 733 sparing and booster shots

COVID super-immunity: one of the pandemic's great puzzles

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis 740 with thrombocytopenia syndrome

Thrombosis in peripheral artery disease and thrombotic thrombocytopenia after 743 adenoviral COVID-19 vaccination

Signal transduction pathway involved in platelet activation in immune 746 thrombotic thrombocytopenia after COVID-19 vaccination

Predictors of mortality in thrombotic thrombocytopenia after adenoviral 749 COVID-19 vaccination: the FAPIC score

Vaccine-induced immune thrombotic thrombocytopenia after 752 vaccination against Covid-19: A clinical dilemma for clinicians and patients

Thrombotic Thrombocytopenia after COVID-19 755 Vaccination

Thrombotic Thrombocytopenia after 758 COVID-19 Janssen Vaccination

Safety, immunogenicity, and efficacy of a COVID-19 vaccine

CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of 761 a randomised, observer-blinded, placebo-controlled, phase 3 trial

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

The Novavax vaccine against COVID-19: What you need to know

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 771 spike

SARS-CoV-2 immunity: review and 773 applications to phase 3 vaccine candidates

Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic 776 Infectious Diseases. Precautions or Contraindications for Rabies Vaccination. Accessed 777 on

A Phase 1, Open label, Dose escalation, Randomized, Multicenter Study to Evaluate the 781

Safety, and Immunogenicity of an Intramuscular inactivated rabies 782 vector platform Corona Virus Vaccine (rDNA-BBV151) in Healthy Volunteers . Enrollment 783 date